Cover Image
市場調查報告書

酒精成癮(酒精中毒):開發平台分析

Alcohol Addiction - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213101
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
酒精成癮(酒精中毒):開發平台分析 Alcohol Addiction - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 124 Pages
簡介

所謂酒精成癮(酒精中毒)是指心理性·肉體性對酒精的依賴狀態。主要的症狀有社會活動的參與度低和憂鬱症,不安狀態,無法克制飲酒的欲望,暴力行為等。

本報告提供全球各國治療酒精成癮(酒精中毒)用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

酒精成癮(酒精中毒)概要

治療藥的開發

  • 酒精成癮(酒精中毒)開發中產品:概要
  • 酒精成癮(酒精中毒)開發中產品:比較分析

各企業正在開發的酒精成癮(酒精中毒)治療藥

大學/研究機關研究中的酒精成癮(酒精中毒)治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

酒精成癮(酒精中毒)治療藥:開發中的產品一覽(各企業)

按酒精成癮(酒精中毒)治療藥:研究中的產品一覽(大學/研究機關)

酒精成癮(酒精中毒)開發治療藥的企業

酒精成癮(酒精中毒):治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

酒精成癮(酒精中毒)治療藥:開發中產品的最新趨勢

酒精成癮(酒精中毒)治療藥:開發暫停的產品

酒精成癮(酒精中毒)治療藥:開發中止的產品

酒精成癮(酒精中毒)相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8952IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Pipeline Review, H1 2017, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 10, 1, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Alcohol Addiction - Overview
  • Alcohol Addiction - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Alcohol Addiction - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Alcohol Addiction - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Adial Pharmaceuticals LLC
  • Astraea Therapeutics LLC
  • BioCorRx Inc
  • Bionex Pharmaceuticals LLC
  • Bioprojet SCR
  • Cerecor Inc
  • Chronos Therapeutics Ltd
  • Corcept Therapeutics Inc
  • Curemark LLC
  • Eli Lilly and Company
  • Ethypharm SA
  • Euthymics Bioscience Inc
  • H. Lundbeck A/S
  • Heptares Therapeutics Ltd
  • Indivior Plc
  • Kinnov Therapeutics SAS
  • Kyorin Pharmaceutical Co Ltd
  • Lohocla Research Corp
  • Omeros Corp
  • Pfizer Inc
  • Savant HWP Inc
  • SK Biopharmaceuticals Co Ltd
  • Tonix Pharmaceuticals Holding Corp
  • VM Discovery Inc
  • XenoPort Inc
  • Zynerba Pharmaceuticals Inc
  • Alcohol Addiction - Drug Profiles
  • (cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (disulfiram + selegiline) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • 18-MC - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • A-705253 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABT-436 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ADX-71441 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • amitifadine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • arbaclofen placarbil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • baclofen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • carisbamate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CERC-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CM-1212 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CTDP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • gabapentin enacarbil ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GET-73 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ibudilast - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JDTic - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nalmefene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naltrexone hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naltrexone hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naltrexone hydrochloride SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • odelepran hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OMS-527 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ondansetron hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-05190457 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pitolisant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SKL-10406 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Alcohol Addiction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VMD-2202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Alcohol Addiction - Dormant Projects
  • Alcohol Addiction - Discontinued Products
  • Alcohol Addiction - Product Development Milestones
  • Featured News & Press Releases
  • Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence
  • Nov 28, 2016: BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA
  • Sep 15, 2016: BioCorRx Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product
  • Sep 03, 2016: Baclofen helps reduce the consumption of alcohol in alcohol - dependent patients
  • Aug 31, 2016: BioCorRx Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology
  • Jul 25, 2016: Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
  • Jul 20, 2016: Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health
  • Jul 14, 2016: BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant
  • Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
  • May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
  • Jan 14, 2016: BioCorRx Announces New Agreements With Wellness Centers in Slidell, LA, Memphis and Nashville, TN, and Philadelphia, PA
  • Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
  • Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
  • Dec 07, 2015: BioCorRx Announces Agreements With Additional Wellness Centers in California, Wisconsin and Arizona
  • Oct 13, 2015: Addex' ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Alcohol Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Alcohol Addiction - Pipeline by AbbVie Inc, H1 2017
  • Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Alcohol Addiction - Pipeline by Adial Pharmaceuticals LLC, H1 2017
  • Alcohol Addiction - Pipeline by Astraea Therapeutics LLC, H1 2017
  • Alcohol Addiction - Pipeline by BioCorRx Inc, H1 2017
  • Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2017
  • Alcohol Addiction - Pipeline by Bioprojet SCR, H1 2017
  • Alcohol Addiction - Pipeline by Cerecor Inc, H1 2017
  • Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, H1 2017
  • Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, H1 2017
  • Alcohol Addiction - Pipeline by Curemark LLC, H1 2017
  • Alcohol Addiction - Pipeline by Eli Lilly and Company, H1 2017
  • Alcohol Addiction - Pipeline by Ethypharm SA, H1 2017
  • Alcohol Addiction - Pipeline by Euthymics Bioscience Inc, H1 2017
  • Alcohol Addiction - Pipeline by H. Lundbeck A/S, H1 2017
  • Alcohol Addiction - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Alcohol Addiction - Pipeline by Indivior Plc, H1 2017
  • Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS, H1 2017
  • Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Alcohol Addiction - Pipeline by Lohocla Research Corp, H1 2017
  • Alcohol Addiction - Pipeline by Omeros Corp, H1 2017
  • Alcohol Addiction - Pipeline by Pfizer Inc, H1 2017
  • Alcohol Addiction - Pipeline by Savant HWP Inc, H1 2017
  • Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017
  • Alcohol Addiction - Pipeline by VM Discovery Inc, H1 2017
  • Alcohol Addiction - Pipeline by XenoPort Inc, H1 2017
  • Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
  • Alcohol Addiction - Dormant Projects, H1 2017
  • Alcohol Addiction - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Alcohol Addiction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Alcohol Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top